Press release
Advanced Kidney Cancer Clinical Pipeline | 50+ Companies Transforming the Future of Treatment
Advanced Kidney Cancer Clinical Pipeline
DelveInsight's 'Advanced Kidney Cancer Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Advanced Kidney Cancer therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Advanced Kidney Cancer pipeline domain.
For emerging Advanced Kidney Cancer drugs, the Advanced Kidney Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Advanced Kidney Cancer Pipeline Report
• DelveInsight's Advanced Kidney Cancer Pipeline analysis depicts a robust space with 50+ active players working to develop 55+ pipeline drugs for Advanced Kidney Cancer treatment.
• The leading Advanced Kidney Cancer companies include Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics, Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune, and others are evaluating their lead assets to improve the Advanced Kidney Cancer treatment landscape.
• Key Advanced Kidney Cancer pipeline therapies in various stages of development include Savolitinib, Relatlimab, JANX008, TQB2450, Tc-99m Pentetate, BMS-986488, Belzutifan, DFF332, RAD001, PDR001, NIR178, Atezolizumab, Zanzalintinib, and others.
• In Feb 2025, Telix Pharmaceuticals announced that the FDA accepted the Biologics License Application (BLA) for TLX250-CDx (Zircaix®), a breakthrough kidney cancer PET imaging agent. The FDA granted a Priority Review and set a PDUFA date of August 27, 2025, for a potential U.S. launch.
Request a sample and discover the recent breakthroughs happening in the Advanced Kidney Cancer pipeline landscape @ https://www.delveinsight.com/report-store/advanced-kidney-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Advanced Kidney Cancer Overview
Advanced kidney cancer, primarily advanced renal cell carcinoma (RCC), is the most common kidney cancer in adults, accounting for over 90% of cases. Other types include transitional cell carcinomas of the renal pelvis, which resemble bladder cancers, and the rare renal sarcoma. Major risk factors for RCC include smoking, obesity-particularly in women-high blood pressure, chronic renal failure, and occupational exposure to harmful chemicals. Reducing tobacco use and excess body weight could significantly lower RCC incidence. Conversely, moderate alcohol intake, a diet rich in fruits and vegetables, and long-term fatty fish consumption are associated with a lower risk. Genetic mutations also play a role, with VHL mutations linked to both sporadic and familial clear cell RCC, while MET mutations are characteristic of familial papillary RCC.
Managing advanced or metastatic RCC requires a multidisciplinary approach, involving oncology specialists, nurses, dietitians, and pharmacists to optimize treatment and monitor toxicities. Accurate staging is essential for effective management, guiding treatment decisions. Early-stage RCC (Stage 1a and 1b) is typically treated with nephron-sparing surgery or radical nephrectomy, followed by imaging surveillance. Stages 2 and 3 often require radical nephrectomy with structured follow-ups. In Stage 4, systemic targeted therapies like VEGF-TKIs and rapamycin inhibitors are preferred, while nephrectomy combined with immunotherapy has shown improved survival outcomes. Regular imaging and patient evaluations ensure treatment efficacy and safety, emphasizing the importance of comprehensive patient education on side effects and management strategies.
Find out more about Advanced Kidney Cancer medication @ https://www.delveinsight.com/report-store/advanced-kidney-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Advanced Kidney Cancer Treatment Analysis: Drug Profile
Savolitinib: AstraZeneca
Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations or gene amplification. The drug is currently being evaluated under Phase III clinical trial for the treatment of advanced kidney cancer.
Relatlimab: Bristol-Myers Squibb
Relatlimab is a lymphocyte activation gene-3 (LAG-3) blocking antibody and is expressed in a recombinant CHO cell line. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with advanced kidney cancer.
Key Advanced Kidney Cancer Therapies and Companies
• Savolitinib: AstraZeneca
• Relatlimab: Bristol-Myers Squibb
• JANX008: Janux Therapeutics
• TQB2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Tc-99m Pentetate: NYU Langone Health
• BMS-986488: Bristol-Myers Squibb
• Belzutifan: Merck Sharp & Dohme LLC
• DFF332/RAD001/PDR001/ NIR178: Novartis Pharmaceuticals
• Atezolizumab: Hoffmann-La Roche
• Zanzalintinib: Qian Qin
Learn more about the novel and emerging Advanced Kidney Cancer pipeline therapies @ https://www.delveinsight.com/report-store/advanced-kidney-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Advanced Kidney Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide
Scope of the Advanced Kidney Cancer Pipeline Report
• Coverage: Global
• Key Advanced Kidney Cancer Companies: Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics, Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune, and others.
• Key Advanced Kidney Cancer Pipeline Therapies: Savolitinib, Relatlimab, JANX008, TQB2450, Tc-99m Pentetate, BMS-986488, Belzutifan, DFF332, RAD001, PDR001, NIR178, Atezolizumab, Zanzalintinib, and others.
Dive deep into rich insights for drugs used for Advanced Kidney Cancer treatment; visit @ https://www.delveinsight.com/report-store/advanced-kidney-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Advanced Kidney Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Advanced Kidney Cancer Pipeline Therapeutics
6. Advanced Kidney Cancer Pipeline: Late-Stage Products (Phase III)
7. Advanced Kidney Cancer Pipeline: Late-Stage Products (Phase III)
8. Advanced Kidney Cancer Pipeline: Mid-Stage Products (Phase II)
9. Advanced Kidney Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Kidney Cancer Clinical Pipeline | 50+ Companies Transforming the Future of Treatment here
News-ID: 3922234 • Views: …
More Releases from DelveInsight
Insulin Resistance Pipeline Insight 2025: Pipeline Drugs, Metabolic Pathway Modu …
DelveInsight's "Insulin Resistance - Pipeline Insight, 2025" explores over 10+ therapies in development for insulin resistance, a metabolic condition strongly linked to type 2 diabetes, obesity, and cardiovascular disease. Despite lifestyle modification and insulin-sensitizing drugs like metformin being mainstays of management, many patients continue to face poor glycemic control and associated complications, underscoring the need for more effective insulin resistance treatments.
The insulin resistance pipeline is broadening with next-generation therapies targeting…
Uveal Melanoma Pipeline Insight 2025: 30+ Pipeline Drugs, Targeted Therapies, an …
DelveInsight's "Uveal Melanoma - Pipeline Insight, 2025" explores over 30+ therapies in development for uveal melanoma, a rare and aggressive intraocular malignancy with high metastatic potential, most commonly to the liver. Despite surgery and radiotherapy being standards for localized disease, patients with metastatic uveal melanoma face limited systemic treatment options, creating significant unmet needs in the uveal melanoma treatment landscape.
The uveal melanoma pipeline is diversifying with next-generation targeted therapies, including…
Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shap …
DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs,…
Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trial …
DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.
The VOC pipeline is diversifying with…
More Releases for Advanced
Advanced Oxidation Technologies Market Size, Share 2021, Impressive Industry Gro …
The Advanced Oxidation Technologies Market is poised to take off in upcoming years hence showing a highly positive outlook through 2020-2028, according to a recently released report. Advanced Oxidation Technologies Market report covers industry chain analysis, latest market trends & dynamics along with cost profit analysis of major key players which focuses on expansion rate, prices, competition, size, prices, and value chain analysis of those leaders in the market.
The…
Medical Ceramics Market Analysis and Industry Forecast | Advanced Ceramics Resea …
Allied Market Research published a new report, titled, “Medical Ceramics Market by Type (Aluminum Oxide, Zirconia, and Carbon, Hydroxyapatite, Glass & Bioglass, Zirconia Alumina, Bioresorbable Ceramics, and Piezo Ceramics), by Application (Surgical Instruments, Diagnostic Equipment, Orthopedic Implants, Electronic Implants, Dental Implants, Disposables, and Packaging) – Global Opportunity Analysis and Industry Forecast, 2014 – 2022.” The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter’s Five…
Skincell Advanced Reviews – Does Skincell Advanced Really Work?
People want clear, blemish-free skin! However, most people have skin tags, moles, and warts. Some causes are known, while some blemishes are caused without any reason at all. When a regular skincare regimen fails, people turn to costly surgeries and medications. Cleansing and moisturizing might not work well for all. All skin types are not the same, and toners and skincare creams seldom give long-lasting benefits.
Get Skincell Advanced From Its…
Global Advanced Oxidation Technologies Market 2019- 2025 || A-Zone Technologies, …
Synopsis of the Advanced Oxidation Technologies Market:
Latest Report on Advanced Oxidation Technologies Market deliberates the effect of various Factors influencing the market growth and drivers. Its further sheds light on market overview, key manufacturers, strategic adopted by them, size, latest trends and types, revenue, gross margin with regional analysis and forecast to 2025.
Overview of the Advanced Oxidation Technologies Market Report:
Advanced Oxidation Technologies Market report includes knowledge about the market overview…
Global Advanced Materials Market - 3M Company, DowDuPont Inc, Hexcel Corporation …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market - By Product type (Structural Material, Functional Material, Emerging Material) By End User (Building & Construction, Automotive, Aerospace, Defense, Marine, Electrical & Electronics, Healthcare, Oil & Gas and Energy, Others) & Global Region - Market Size, Trends, Share and Forecast 2018-2023” research report will include all the major trends and technologies that…
Global Advanced Materials Market: 3M Company, DowDuPont Inc, Hexcel Corporation, …
A New fresh research report presented by KD Market Insights provides a detailed analysis of “Advanced Materials Market 2017: Market Size, Trends & Opportunity Outlook – Forecast to 2023” research report will include all the major trends and technologies that play an important role in market growth in the predicted span of 6 years. It also presents the overview of industry players, advantages, challenges the business is going through. The…
